Evidence map›Paper›PMID 41272456›Full record

ArticleBMC genomics2025

An audit of the PeptideAtlas database uncovers evidence for repurposed pseudogenes and co-opted retroviral ORFs.

Jose Manuel Rodriguez, Miguel Maquedano, Daniel Cerdán-Vélez, Andrea Laguillo-Gómez, Enrique Calvo, Federico Abascal, Jesús Vázquez, Michael L Tress

Abstract read
In one paragraph

Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jose Manuel RodriguezCardiovascular Proteomics Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, 28029, Spain.
Miguel MaquedanoBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, 28029, Spain.
Daniel Cerdán-VélezBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, 28029, Spain.
Andrea Laguillo-GómezCardiovascular Proteomics Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, 28029, Spain.
Enrique CalvoCardiovascular Proteomics Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, 28029, Spain.
Federico AbascalWellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Jesús VázquezCardiovascular Proteomics Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, 28029, Spain. jesus.vazquez@cnic.es.
Michael L TressBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, 28029, Spain. mtress@cnio.es.

Funding

GENCODE Resource ProjectU41HG007234 · NHGRI · SANGER INSTITUTE · PI FLICEK, PAUL · 2013 to 2020
$20.3M
Comunidad de Madrid S2022/BMD-7333-CM'la Caixa' Foundation LCF/PR/HR22/52420019Ministerio de Ciencia, Innovación y Universidades PID2021-122348NB-I00NHGRI NIH HHS U41 HG007234
6 · The paper itself

Abstract

backgroundThe human genome has been the subject of scrutiny for more than two decades, yet new protein coding genes are still being uncovered. Recently ribosome profiling experiments have provided evidence for the translation of thousands of novel open reading frames (ORFs). To determine how many of these novel ORFs have peptide support, we carried out an in-depth investigation of an entire mass spectrometry proteomics database.

resultsWe analysed the peptides housed in the human build of the PeptideAtlas database and identified reliable evidence for 35 potential coding genes not annotated in the Ensembl/GENCODE reference gene set. Evidence from complementary sources confirmed that 16 were almost certainly coding genes, but we believe that at least 14 are most likely to be undergoing aberrant translation. These 14 genes had reading frames that were not preserved beyond human and their peptides were restricted to cancers or cell lines. Remarkably, three of the sixteen likely coding genes were derived from endogenous retroviral gag ORFs and were expressed only in placenta. All three had evidence of purifying selection. Retroviral env ORFs (syncytins) with distinct origins are expressed in almost all mammalian placentae and these results suggest that co-opted gag ORFs may also play an important role in placental development.

conclusionsOur analysis shows that proteomics data can be used in conjunction with evolutionary evidence to confirm the existence of new coding genes. The evidence suggests that both testis and placenta are the tissues most likely to express still to be identified coding genes, and that there may be other transposon-derived ORF that have been co-opted as coding genes. The strong evidence for the translation of regions under dysregulated conditions has important implications for the annotation of coding genes and in the analysis of cancer and other degenerative diseases.

Indexed as

Databases, GeneticOpen Reading FramesPseudogenesRetroviridaeAnimalsBiocurationEvolution, MolecularFemaleHumansProteomicsRibosome ProfilingCoding genesCo-optionEndogenous retrovirusProteomicsPseudogenes

Identifiers

PMID41272456
PMCPMC12679747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.